Trump stated that the size of the proposed investment will be announced within the next two weeks, when South Korean President Lee Jae Myung visits the White House for bilateral talks.
Xtrackers SPXD ETF offers a balanced way to invest in S&P 500 without relying on tech giants like Nvidia. Its innovative approach prioritizes actual economic activity and has affordable fees.
XRP has risen 6.4% in the past 24 hours, reaching $3.22 amid growing optimism surrounding potential digital asset ETF approvals expected by mid-August. Increased institutional trading activity and a notable uptick in Asian exchange volume have contributed to the rally, highlighting continued interest in utility-driven cryptocurrencies.
Shares of water management solutions company Zurn Elkay (NYSE:ZWS)
jumped 15.2% in the afternoon session after the company reported strong second-quarter 2025 financial results that surpassed expectations and raised its full-year guidance. The water solutions provider announced net sales of $445 million, an 8% increase year-over-year that surpassed analyst expectations. Profitability also showed significant strength, with adjusted earnings per share (EPS) growing 27% to $0.42 and adjusted EBITDA margins expanding. Buoyed by the strong performance, Zurn Elkay raised its full-year 2025 outlook for sales, adjusted EBITDA, and free cash flow. The company also demonstrated confidence by repurchasing $33 million worth of its stock during the quarter. This robust corporate performance occurred despite mixed conditions in the broader Industrials sector, and the positive investor sentiment pushed the stock to a new 52-week high.
Shares of medical device company Penumbra (NYSE:PEN)
jumped 11.8% in the afternoon session after the company reported impressive second-quarter financial results that surpassed analyst expectations and raised its full-year revenue forecast. The company posted revenue of $339.5 million, a 13.4% increase year-over-year, which beat the consensus estimate of $327.77 million. Earnings per share also came in strong at $0.86, topping expectations of $0.83. This growth was primarily fueled by its U.S. Thrombectomy business, which involves procedures to remove blood clots and saw a 22.6% revenue jump. The embolization segment, which deals with blocking blood flow for treatment, also performed well. Bolstered by this strong performance, Penumbra lifted its full-year 2025 revenue guidance, signaling confidence in its continued growth trajectory.
Gold has been a hot commodity, pun intended, with the SPDR Gold Shares ETF up 42% over the last 12 months. While we hope the trend continues, gold can remain stagnant for an extended period, and income-producing gold-focused funds can be appealing.
Meta Platformsis expected to report its 11th consecutive revenue beat, attracting attention from stock pickers and ETF investors due to its growing presence in Big Tech and AI-themed ETFs.
In a post on Truth Social, President Donald Trump called India’s tariffs “among the highest in the world” and criticized its purchases of Russian energy and military equipment.
United States, July 30, 2025 -- XRP is once again at the center of market attention, currently trading between $3.16–$3.20 following a strong early-July rally. Market analysts forecast a potential +333% move toward $13 within 40 days, citing renewed ETF optimism, favorable legal shifts, and rising institutional accumulation — including over $25 million in long positions. Even after a brief 7% dip on delayed SEC decisions, XRP remains one of the most-watched assets for its breakout potential and strategic positioning in the evolving regulatory landscape.
Astera Capital officially unveiled its renewed brand proposition and elite advisory team today, marking a new chapter in the company’s global strategy and high-end capital services. This announcement not only reinforces Astera’s long-standing commitment to serving and educating global high-net-worth investors, but also embodies its core philosophy: “Strategy as the Foundation, Trust as the Principle.” The initiative further solidifies its positioning as a cross-market asset allocation specialist and trusted wealth advisor.
